News

Spineart today announces that it has completed a planned interim analysis for its 2-level BAGUERA® C IDE study, which showed that BAGUERA® C, its innovative cervical disc prosthesis, met the threshold for a non-inferiority claim against the study control.

Last month, Spineart announced that its interim analysis for its 1-level BAGUERA®C IDE study had also showed that BAGUERA® C had met the threshold for a non-inferiority claim against the study control and that it had agreed on a timeline with the U.S. FDA for the submission of a modular Premarket Approval (PMA) for BAGUERA® C.

Spineart has agreed with the U.S. FDA to submit the interim results from both IDE studies under the same PMA. Completion of this combined PMA submission remains scheduled for the end of August 2025, potentially enabling an earlier approval than had originally been anticipated.

The BAGUERA®C 1-level and 2-level IDE trials are prospective, multi-center, randomized clinical studies evaluating the safety and efficacy of BAGUERA®C compared with the Mobi-C® cervical disc in the treatment of symptomatic cervical disease at one level and two contiguous levels in the cervical spine. The studies enrolled close to 600 patients at 30 sites in the U.S. Results of these clinical trials are intended to be the basis of a PMA submission to the U.S. FDA.

Jerome Trividic, Chief Executive Officer at Spineart, commented: “The interim analysis data from our 2-level study is a significant milestone for Spineart, coming less than a month after the promising interim results of our 1-level study. These findings bring us closer to providing patients with a highly effective solution for treating symptomatic cervical disease at multiple levels, potentially improving their quality of life. We are committed to advancing spinal health and working with the FDA to bring BAGUERA® C to patients in the United States.”

CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use.

Spineart and eCential Robotics proudly announce the 510(k) clearance from the U.S. Food and Drug Administration (FDA) of the Spineart PERLA® TL application (PERLA® App) for use with the new eCential Robotics Op.n^TM robotic navigation platform.

This clearance marks a significant milestone in advancing robotic-assisted spine surgery and demonstrating new ways to innovate by combining Spineart’s and eCential Robotics’ expertise. The newly approved PERLA® App, which further integrates the Spineart PERLA® TL Open and MIS screw systems with the eCential Op.n^TM platform, offers a Spineart navigation-specific interface and dedicated Spineart navigated instruments, aiming to enhance surgical precision and procedural workflow. Additionally, by expanding the range of 3D C-arms compatible with the system, Spineart and eCential underscore their ability to provide cutting-edge solutions while optimizing available resources at medical facilities through modular solutions.

“We are excited to announce the 510(k) clearance for our first PERLA® App on the eCential Op.n^TM platform. This underscores our commitment to delivering advanced procedural solutions to spine surgeons, ultimately benefiting their patients. Our partnership with eCential Robotics in surgical and robotic navigation has empowered us to pursue an innovative approach that enhances precision and workflow efficiency in the operating room while utilizing our implants and instruments for spine surgery.” said Jerome Trividic, CEO of Spineart.

“This 510(k) clearance shows our dedication to innovation and increasing the capabilities and modularity of our Op.n^TM platform for surgical and robotic navigation,” said Clement Vidal, CEO of eCential Robotics. “By combining our partner Spineart’s spine systems with our expertise in advanced robotic navigation, we are bringing a transformative solution to the operating room, benefiting both surgeons and patients while optimizing cost for medical facilities.”

Building on this successful collaboration, Spineart and eCential Robotics will continue to join forces to drive further innovation on the Op.n^TM platform.

Spineart today announces that it has completed a planned interim analysis for its 1-level BAGUERA®C IDE study, which showed that      BAGUERA® C, its innovative cervical disc prosthesis, met the threshold for a non-inferiority claim against the study control.

Spineart has now agreed on a timeline with the U.S. FDA for the submission of Premarket Approval (PMA) for BAGUERA® C in three components (modules) which will be submitted and reviewed separately. Completion of the PMA submission is now scheduled for the end of August 2025, potentially enabling an earlier approval than had originally been anticipated.

The BAGUERA® C 1-level IDE trial is a prospective, multi-center, randomized clinical study evaluating the safety and efficacy of BAGUERA® C compared with the Mobi-C® cervical disc in the treatment of symptomatic cervical disease at a single level in the cervical spine. The study enrolled 285 patients at 25 sites in the U.S. Results of this clinical trial are intended to be the basis of a PMA submission to the U.S. FDA.

Jerome Trividic, Chief Executive Officer at Spineart, commented: “This interim analysis data is extremely promising. We look forward to working with the FDA as we prepare to submit our PMA modules later this year, bringing us closer to making our innovative cervical disc prosthesis available to patients in the United States.”

CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use.

About the BAGUERA® C Cervical Disc Prosthesis

The BAGUERA® C cervical disc prosthesis, developed by Spineart, is an investigational device in the U.S., designed to maintain or restore segmental motion and disc height in the cervical region of the spine following single- or two-level discectomy for symptomatic cervical disc disease. The BAGUERA® C is designed to maintain the natural behavior of a functional spinal unit. This design enables the BAGUERA®C nucleus to move in all six degrees of freedom, with independent angular rotations (flexion-extension, lateral bending, and axial rotation) along with independent translational motions (anterior-posterior and lateral translations).

Spineart today announces that it has completed a planned interim analysis for its 1-level BAGUERA®C IDE study, which showed that      BAGUERA® C, its innovative cervical disc prosthesis, met the threshold for a non-inferiority claim against the study control.

Spineart has now agreed on a timeline with the U.S. FDA for the submission of Premarket Approval (PMA) for BAGUERA® C in three components (modules) which will be submitted and reviewed separately. Completion of the PMA submission is now scheduled for the end of August 2025, potentially enabling an earlier approval than had originally been anticipated.

The BAGUERA® C 1-level IDE trial is a prospective, multi-center, randomized clinical study evaluating the safety and efficacy of BAGUERA® C compared with the Mobi-C® cervical disc in the treatment of symptomatic cervical disease at a single level in the cervical spine. The study enrolled 285 patients at 25 sites in the U.S. Results of this clinical trial are intended to be the basis of a PMA submission to the U.S. FDA.

Jerome Trividic, Chief Executive Officer at Spineart, commented: “This interim analysis data is extremely promising. We look forward to working with the FDA as we prepare to submit our PMA modules later this year, bringing us closer to making our innovative cervical disc prosthesis available to patients in the United States.”

CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use.

About the BAGUERA® C Cervical Disc Prosthesis

The BAGUERA® C cervical disc prosthesis, developed by Spineart, is an investigational device in the U.S., designed to maintain or restore segmental motion and disc height in the cervical region of the spine following single- or two-level discectomy for symptomatic cervical disc disease. The BAGUERA® C is designed to maintain the natural behavior of a functional spinal unit. This design enables the BAGUERA®C nucleus to move in all six degrees of freedom, with independent angular rotations (flexion-extension, lateral bending, and axial rotation) along with independent translational motions (anterior-posterior and lateral translations).

Spécialisée dans la conception de dispositifs médicaux implantés dans la colonne vertébrale,
la société genevoise regroupe tous ses sites de production haut-savoyards à Reignier.

Affichant une croissance annuelle à deux chiffres, le groupe Spineart déploie une forte présence à l’international, avec pas moins de 60 pays destinataires de ses produits. Et des implantations dans le monde entier : le siège social à Genève, en Haute-Savoie pour la partie production, des bureaux en Europe, en Californie pour le marché américain, ainsi qu’une ouverture prochaine du “Spineart Innovation Center” à Dallas, Texas. «À Plan-les-Ouates (Genève), nous avons la R&D, le marketing et tous les services supports du groupe», détaille Gino Poggiali, directeur administratif et responsable du siège social. Le site est en expansion avec l’ajout de près de 750 m2 de bureaux, dont le bail vient d’être signé. «Nous prévoyons d’embaucher une quarantaine de personnes en plus des 120 actuelles, sur le site de Genève, dans les trois ou quatre ans à venir», complète le PDG du groupe, Jérôme Trividic. Un développement destiné à répondre à la forte croissance de cette société dans le domaine des dispositifs médicaux implantables, qui se situe au douzième rang des entreprises mondiales de ce secteur.

DOUBLER LA CAPACITÉ DE PRODUCTION
En Haute-Savoie, deux sites, Archamps, pour la partie packaging et logistique, et Fillinges, pour la fabrication des pièces, sont en cours de regroupement dans un nouveau bâtiment situé à Reignier qui s’étend sur 4300 m2. Un quasi-doublement de la surface pour répondre à des besoins de production multipliés par deux. Les effectifs seront tous rassemblés sur le même site et devraient passer de 65 à 85 personnes dans les années à venir. «L’investissement rien que pour le bâtiment s’élève à 6,50 millions d’euros », précise Gino Poggiali. «Et près de deux millions pour les machines », ajoute le PDG, notamment des tours et des multi-axes pour l’usinage, et des imprimantes 3D pour le titane poreux. «Une ligne de production complète est d’ores et déjà en fonctionnement dans le but d’obtenir les certifications du site et de l’outil de production», poursuit Jérôme Trividic, pointant les exigences du secteur médical. Un audit est prévu pour fin novembre avec l’obtention du précieux sésame espéré avant la fin du premier trimestre 2025.
«Spineart est une entreprise pilote dans le cadre du Medical Device Regulation (MDR) de l’Union européenne. Les règles ont évolué et la barre est remontée très haut. Nous avons l’expérience car ce règlement a été appliqué pour nos différents sites et produits. Nous arrivons très préparés pour cet audit. »
Le groupe affiche en 20 ans plus de 50 produits lancés et une vingtaine de projets de développement en cours. «Nous avons d’importants investissements stratégiques aux Etats-Unis sur une prothèse de disque cervicale par exemple, dont les études en Europe affichent de très bons retours cliniques », avec la soumission d’une demande d’autorisation de mise sur le marché américain prévue pour 2026.
Ainsi que des innovations sur les aspects robotiques et assistances robotisées dans le médical via des collaborations avec des start-up grenobloises. Autant de développements annonçant une actualité chargée pour ce groupe en pleine expansion dans les mois et les années à venir.

Sandra Molloy

Article de L’Extension – Hiver 2024

Spineart announces that it has reached the significant milestone of 100,000 Ti-LIFE Technology cages sold worldwide, supporting the Company’s mission to transform spine surgery for surgeons, patients and hospitals in more than 60 global markets.

Launched in July 2016, Spineart’s Ti-LIFE Technology is based on a unique proprietary algorithm associated with a state-of-the art additive (3D printing) manufacturing process. Ti-LIFE is applied across a range of Spineart’s surgical implants, including posterior, lateral and cervical cages – hollow interbody devices used in spinal fusion surgeries. These cages act as a space holder between the vertebrae, helping to decompress the spinal cord and nerve root.

Ti-LIFE’s micro-porous structure closely mimics the architecture of the natural trabecular bone and is designed to promote osseous in-growth and cell colonization once implanted. Cages featuring the Ti-LIFE Technology have been shown to outperform other materials, demonstrating early and robust osseointegration without any bone graft or additive osteoinductive agents in just eight weeks.*

“Since its launch in 2016, Spineart’s Ti-Life Technology has contributed significantly to setting a new benchmark in spinal fusion surgery around the world,” remarked Jerome Trividic, Chief Executive Officer at Spineart. “As we progress towards the 20-year anniversary of the founding of our company, this latest milestone reflects our unwavering commitment to transforming spine surgery and improving patient lives, as well as Ti-LIFE’s excellent surgical track record.”

“Spineart’s Ti-LIFE Technology offers significant improvements over traditional titanium implants, with better osseointegration, customizable mechanical properties, and improved imaging capabilities, all of which contribute to enhanced patient outcomes in spinal fusion surgery,” said Joseph Laratta, MD, minimally invasive orthopedic spine surgeon at the Neck and Back Institute of Kentucky.

“Surpassing the 100,000 sales milestone for our Ti-LIFE Technology cages is a powerful demonstration of our strong growth to date as well as our future potential. Thank you to our team, investors, partners, surgeons and customers, each of whom have worked alongside us to reach this goal,” added Alessia Erlingher, Chief Commercial Officer at Spineart.

To learn more about Ti-LIFE Technology: https://www.spineart.com/technology/ti-life-technology/

References:

* Joseph L. Laratta, MD et al. 3D-printed titanium cages without bone graft outperform PEEK cages with autograft in an animal model. The Spine Journal. 2021; DOI.